Harbour BioMed (HKEX: 02142), a global biopharmaceutical company specializing in novel antibody therapeutics for immunology and oncology, has announced that it will present Phase II clinical data on its anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab for microsatellite stable $(MSS)$ metastatic colorectal cancer (mCRC). The presentation will take place at the ESMO Congress 2025 in Berlin, Germany, from October 17-21, 2025. The study, conducted at multiple centers, involved heavily pretreated non-liver metastatic MSS mCRC patients. Preliminary efficacy and safety data will be featured in a poster session. Porustobart, developed using the HCAb Harbour Mice® platform, offers unique properties such as significant Treg cell depletion and optimized pharmacokinetics. The company has observed positive efficacy and safety data in monotherapy and combination trials for various solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.